株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

幹細胞エクソソーム市場

The Market for Stem Cell Exosomes

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 587814
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
幹細胞エクソソーム市場 The Market for Stem Cell Exosomes
出版日: 2017年12月15日 ページ情報: 英文 134 Pages
概要

当レポートでは、幹細胞由来エクソソーム市場について調査し、幹細胞由来エクソソームの種類、エクソソームの治療効果、癌における幹細胞エクソソームの役割、ソーシャル分析、エクソソーム技術開発企業・エクソソーム研究製品開発企業のプロファイル、SWOT分析、投資環境、および市場規模の予測などをまとめています。

第1章 要約

第2章 調査方法

第3章 調査目的

第4章 エクソソームの主な特徴

第5章 幹細胞由来エクソソームの種類

第6章 エクソソームのメリット

第7章 エクソソームの治療効果

  • 標的細胞の成長への影響
  • 表現型への影響
  • 細胞運命決定への関与
  • 再生の促進
  • 免疫修飾
  • 抗炎症効果
  • 抗線維化効果

第8章 癌における幹細胞エクソソームの役割

  • 腫瘍血管新生における役割
  • 腫瘍湿潤・転移における役割
  • 腫瘍バイオマーカーにおける役割

第9章 エクソソームの特徴化

第10章 エクソソーム科学出版物の役割 (全細胞種類)

  • エクソソーム科学出版物の分析
  • 幹細胞エクソソーム科学出版物の分析
  • エクソソーム同義語の科学出版率比較

第11章 トレンドデータ

  • 助成金分析
  • 特許分析
  • 治験分析

第12章 ソーシャル分析

  • エクソソームのマーケティングコスト
  • 主なソーシャルメディア記事
  • Googleのトレンド
  • Twitterのデータ

第13章 エクソソーム産業イベントのタイムライン

第14章 エクソソーム技術開発企業のプロファイル

  • Anjarium Biosciences
  • Capricor Therapeutics
  • Codiak Biosciences
  • Creative Medical Technologies Holdings
  • Evox Therapeutics
  • Exerkine Corporation
  • ExoCoBio Inc.
  • Exogenus Therapeutics
  • Exopharm
  • Exosome Diagnostics
  • Exosome Sciences
  • Exosomics Siena SpA
  • Exovita Biosciences
  • Kimera Labs
  • Lonza
  • ReNeuron
  • RoosterBio

第15章 エクソソーム研究製品の開発企業

  • 市場リーダー
  • Google Adwords を用いたエクソソーム研究製品の広告企業
  • エクソソーム研究製品を提供する全企業

第16章 SWOT分析 (強み、弱み、機会、脅威)

  • 強み
  • 弱み
  • 機会
  • 脅威

第17章 投資環境

  • 従来のベンチャーキャピタル投資
  • 産業投資のその他の種類 (提携、M&A、コブランディング)

第18章 市場セグメント

  • 研究製品
  • 診断ツール
  • 治療薬
  • 機能性化粧品
  • 製造サービス

第19章 市場規模の決定

  • 定義
  • 手法
  • 将来の予測:市場セグメント別

第20章 エクソソームの行政監督

  • 米国の幹細胞エクソソーム規制
  • 21st Century Cures Act (21世紀治療法案) および REGROW Act (REGROW法案)
  • 日本における認可手順の迅速化
  • 世界における認可手順の迅速化

第21章 エクソソーム会議・イベント

第22章 結論

付録A:エクソソーム産業の発表

目次

Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.

Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes on PubMed.gov. Today, there are more than 4,400 articles published about exosomes on PubMed.gov, of which approximately 25% were released in the past year.

image1

When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinacomes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles.


image2

When the term "extracellular vesicles" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Prof. Giovanni Camussi.


On the venture capital front, there has also been a great deal of market activity. In January 2016, Exosome Diagnostics closed $60 million in Series B financing, which it followed in July 2017 with $30 million in Series C financing. Similarly, Codiak Biosciences was launched in 2016 when the MD Anderson Cancer Center joined two venture capital firms to form the company with more than $80 million in series A and B financing. On November 29, 2017, Codiak BioSciences added another $76.5 million in Series C financing. In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round.

Companies leading the charge in the area of exosome therapeutics include Anjarium Biosciences, Capricor Therapeutics, Codiak Biosciences, Creative Medical Technology Holdings, Everkine Corporation, Evox Therapeutics, Exogenus Therapeutics, Kimera Labs, ReNeuron, and Unicyte AG, a subsidiary of Fresenius Medical Care.

Numerous life science companies have also launched tools and systems to support exosome research, including Beckman Coulter, Exiqon, System Biosciences (SBI), Lonza, Thermo Fisher, Qiagen, ZenBio, and more. In particular, Lonza made aggressive investments in the sector through its May 2017 acquisition of HansaBioMed Life Sciences and investment into Exosomics.

Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharmand Lonza's strategic acquisitions.

Exosome Market Forces

Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

While exosomes derived from multiple stem cell types are being explored, mesenchymal stem cell (MSC) derived exosomes are best represented within the scientific literature and global patent activity.

To characterize this rapidly forming marketplace, BioInformant has released a 134 page market report that explores growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies. It also reveals trend rate data for exosome patents, grants, scientific publications, andclinical trials, and present social analytics from Google Trends and Google Adwords.

Claim it to:

  • 1. Identify the five market segments that compose the industry
  • 2. Reveal the market players competing in each niche
  • 3. Identify opportunities for exosome product development
  • 4. Access market size determinations and projections through 2022

Companies Mentioned Include:

  • Anjarium Biosciences
  • Avalon GloboCare Corp.
  • Beckman Coulter
  • Capricor Therapeutics
  • Cavadis B.V.
  • Cell Guidance Systems
  • Codiak Biosciences
  • CosmoBio USA
  • Creative Medical Technologies Holdings
  • Exiqon
  • ExoCoBio Inc.
  • Exerkine Corporation
  • Exopharm
  • Exosome Diagnostics
  • Evox Therapeutics
  • Exogenus Therapeutics
  • Exosome Sciences
  • Exosomics Siena SpA
  • Exostemtech Co. Ltd.
  • Exovita Biosciences
  • Galen Lab Supplies
  • Guangzhou Selaira Stem Cell Technology Co., Ltd
  • HansaBioMed Life Sciences
  • iZon Science
  • Kimera Labs
  • Lonza
  • Miltenyi Biotec
  • Norgen Biotek
  • ReNeuron
  • RoosterBio
  • Unicyte AG
  • ZenBio

Table of Contents

1. Abstract

2. Research Methodology

  • 2.1. Input Sources
  • 2.2 Research & Analysis Methodologies

3. Report Purpose

  • 3.1. Survey Recent Advancements with Stem Cell Exosomes
  • 3.2. Provide a "Snapshot" of the Global Market for Stem Cell Exosomes
  • 3.3. Assess Opportunities for Commercialization
  • 3.4. Identify Major Market Players and Assess the Competitive Environment
  • 3.5. Identify Existing and Emerging Trends
  • 3.6. Identify Critical Opportunities and Threats within the Marketplace

4. Key Characteristics of Exosomes

5. Types of Stem Cell Derived Exosomes

6. Advantages of Exosomes

7. Therapeutic Effects of Exosomes

  • 7.1. Influencing Growth of Target Cells
  • 7.2. Influencing Phenotype
  • 7.3. Contributing to Cell Fate Decision
  • 7.4. Promote Regeneration
  • 7.5. Immunomodulation
  • 7.6. Anti-inflammatory Effects
  • 7.7. Anti-fibrotic Effects

8. Role of Stem Cell Exosomes in Cancer

  • 8.1. Role in Tumor Angiogenesis
  • 8.2. Role in Tumor Invasion and Metastasis
  • 8.3. Role in Tumor Biomarkers

9. Exosome Characterization

10. Rates of Exosome Scientific Publications (All Cell Types)

  • 10.1. Analysis of Exosome Scientific Publications (All Cell Types)
  • 10.2. Analysis of Stem Cell Exosome Scientific Publications
  • 10.3. Comparison of Scientific Publication Rates for Exosome Synonyms

11. Trend Data

  • 11.1. Grant Funding Analysis
  • 11.2. Patent Analysis
    • 11.2.1. Patents about Stem Cell Exosomes
    • 11.2.2. Patents about Exosomes (Derived from All Cell Types)
  • 11.3. Clinical Trial Analysis 12. Social Analytics

12. Social Analytics

  • 12.1. Marketing Costs for Exosomes - Google Adwords Price-Per-Click (PPC) Analysis
  • 12.2. Top Social Media Articles (Trailing 12 Months)
  • 12.3. Google Trends
  • 12.4. Twitter Data

13. Timeline of Exosome Industry Events

14. Profiles of Companies Developing Exosome Technologies

  • 14.1. Anjarium Biosciences
  • 14.2. Capricor Therapeutics
  • 14.3. Codiak Biosciences
  • 14.4. Creative Medical Technologies Holdings
  • 14.5. Evox Therapeutics
  • 14.6. Exerkine Corporation
  • 14.7. ExoCoBio Inc.
  • 14.8. Exogenus Therapeutics
  • 14.9. Exopharm
  • 14.10. Exosome Diagnostics
  • 14.11. Exosome Sciences
  • 14.12. Exosomics Siena SpA
  • 14.13. Exovita Biosciences
  • 14.14. Kimera Labs
  • 14.15. Lonza
  • 14.16. ReNeuron
  • 14.17. RoosterBio

15. Companies Developing Exosome Research Products

  • 15.1. Market Leaders
  • 15.2. Companies Advertising Exosome Research Products with Google Adwords
  • 15.3. All Companies Offering Exosome Research Products

16. SWOT Analysis (Strengths, Weaknesses, Opportunities, Threats)

  • 16.1. Strengths of Stem Cell Exosome Market
  • 16.2. Weaknesses of Stem Cell Exosome Market
  • 16.3. Opportunities for the Stem Cell Exosome Market
  • 16.4. Threats to Stem Cell Exosome Market

17. Investment Environment

  • 17.1. Traditional Venture Capital Investments
  • 17.2. Other Types of Industry Investment (Partnerships, M&A, Co-Branding)

18. Market Segments

  • 18.1. Research Products
  • 18.2. Diagnostic Tools
  • 18.3. Therapeutics
  • 18.4. Cosmeceuticals
  • 18.5. Manufacturing Services

19. Market Size Determination

  • 19.1. Definitions
  • 19.2 Methodology
  • 19.3 Future Projections by Market Segment

20. Regulatory Oversight of Exosomes

  • 20.1. U.S. Regulation of Stem Cell Exosomes
  • 20.2. 21st Century Cures Act and REGROW Act
  • 20.3. Accelerated Approval Pathways in Japan 20.4. Accelerated Approval Pathways Worldwide

21. Exosome Conferences and Events

22. Conclusions

Appendix A - Exosome Industry Announcements

Back to Top